Search - tctmd.com

Displaying 861 - 880 of 1511

Sort: Relevancy | Date

Presentation TCT 2014

Short-Duration Versus Guideline-Recommended 12-Month Dual Antiplatelet Therapy After Drug-Eluting Stents Implantation

Presenter: Giulio Stefanini

September 16, 2014

Presentation TCT 2014

Comparison of endothelialization and inflammation between thin- and thick-strut contemporary bioerodable polymer drug-eluting stents and thick-strut fully resorbable scaffolds i___

Presenter: Kazuyuki Yahagi

September 16, 2014

News Industry News

New All-Comers Study Compares Efficacy of Bioresorbable Vascular Scaffold to Best-in-Class Drug Eluting Stents

September 16, 2014

News Industry News

Micell Technologies Highlights Positive Three-Year Data from MiStent SES DESSOLVE Clinical Studies at TCT 2014

September 16, 2014

News Industry News

Medtronic Drug-Coated Balloon Shows Strong Clinical and Economic Benefit in Treatment of Peripheral Artery Disease

September 16, 2014

Presentation TCT 2014

TCT 475: Triple Antithrombotic Therapy Versus Dual Antiplatelet Therapy in Patients with Atrial Fibrillation Undergoing Drug-Eluting Stent Implantation

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Dong Oh Kang

September 15, 2014

Presentation TCT 2014

Do Drug-Eluting Balloons Have Anything to Offer for Bifurcation Treatment? From Theory to Data

Presenter: Bernard R. Chevalier, Leif Thuesen, Ricardo A. Costa, Kenneth Chin

September 15, 2014

Presentation TCT 2014

TCT 181: A Comparative Prospective Analysis of a Drug-Eluting Stent with Biodegradable Polymer Versus a Drug-Eluting Stent with Permanent Polymer in Bifurcation Lesions

Presenter: Bernard R. Chevalier, Leif Thuesen, Ricardo A. Costa, Ran Kornowski

September 15, 2014

Presentation TCT 2014

TCT 652: Incidence and Predictors of Late Catch-up Phenomenon After Drug-Eluting Stent Implantation

Presenter: Alexandre Abizaid, Pieter C. Smits, Robert J. Gil, Masanobu Ohya

September 15, 2014

Presentation TCT 2014

TCT 270: Comparison Among a Drug-Eluting Balloon, Drug-Eluting Stent, and Plain Balloon Angioplasty for Treatment of In-Stent Restenosis: A Network Meta-analysis of 11 Randomized Controlled Trials

Presenter: John A. Bittl, Tullio Palmerini, Joo Myung Lee, MD

September 15, 2014

Presentation TCT 2014

SECURITY: A Prospective, Randomized Trial of Six Months Versus 12 Months of Dual Antiplatelet Therapy Following Coronary Drug-Eluting Stent Implantation

Presenter: Roxana Mehran, Harvey D. White, Antonio Colombo

September 15, 2014

Presentation TCT 2014

ISAR-TRIPLE: A Prospective, Randomized Trial of Six Weeks Versus Six Months of Clopidogrel in Patients Treated with Concomitant Aspirin and Oral Anticoagulant Therapy Following Coronary Drug-Eluting Stent Implantation

Presenter: Roxana Mehran, Harvey D. White, Nikolaus Sarafoff

September 15, 2014

News Conference News TCT 2014

SECURITY: Six-Month DAPT Noninferior to 12 Months with Second-Generation DES

September 15, 2014

News Conference News TCT 2014

Post-discharge Bleeding Common, Predictive of Mortality After PCI

September 15, 2014

News Industry News

New Study Examines the Optimal Duration Time of Dual Anti-Platelet Therapy in Patients with Second-Generation Drug-Eluting Stents

September 15, 2014

News Industry News

New Study Evaluates “Triple Therapy” Regimens After Drug-Eluting Stenting in Patients Requiring Oral Anticoagulation

September 15, 2014

News Conference News TCT 2014

Less Mortality with Paclitaxel-Coated Balloon vs. Stent in DES Restenosis

September 15, 2014

News Conference News TCT 2014

Keynote Address Focuses on Newer DES, Problematic Subgroups

September 15, 2014

News Conference News TCT 2014

COMBO Stent Achieves Neointimal Regression at 24 Months

September 15, 2014

News Industry News

Abbott Initiates ABSORB IV Trial to Evaluate Quality of Life and Cost Savings of Dissolving Heart Device

September 15, 2014

Advertisement

Short-Duration Versus Guideline-Recommended 12-Month Dual Antiplatelet Therapy After Drug-Eluting Stents Implantation

Comparison of endothelialization and inflammation between thin- and thick-strut contemporary bioerodable polymer drug-eluting stents and thick-strut fully resorbable scaffolds i___

New All-Comers Study Compares Efficacy of Bioresorbable Vascular Scaffold to Best-in-Class Drug Eluting Stents

Micell Technologies Highlights Positive Three-Year Data from MiStent SES DESSOLVE Clinical Studies at TCT 2014

Medtronic Drug-Coated Balloon Shows Strong Clinical and Economic Benefit in Treatment of Peripheral Artery Disease

TCT 475: Triple Antithrombotic Therapy Versus Dual Antiplatelet Therapy in Patients with Atrial Fibrillation Undergoing Drug-Eluting Stent Implantation

Do Drug-Eluting Balloons Have Anything to Offer for Bifurcation Treatment? From Theory to Data

TCT 181: A Comparative Prospective Analysis of a Drug-Eluting Stent with Biodegradable Polymer Versus a Drug-Eluting Stent with Permanent Polymer in Bifurcation Lesions

TCT 652: Incidence and Predictors of Late Catch-up Phenomenon After Drug-Eluting Stent Implantation

TCT 270: Comparison Among a Drug-Eluting Balloon, Drug-Eluting Stent, and Plain Balloon Angioplasty for Treatment of In-Stent Restenosis: A Network Meta-analysis of 11 Randomized Controlled Trials

SECURITY: A Prospective, Randomized Trial of Six Months Versus 12 Months of Dual Antiplatelet Therapy Following Coronary Drug-Eluting Stent Implantation

ISAR-TRIPLE: A Prospective, Randomized Trial of Six Weeks Versus Six Months of Clopidogrel in Patients Treated with Concomitant Aspirin and Oral Anticoagulant Therapy Following Coronary Drug-Eluting Stent Implantation

SECURITY: Six-Month DAPT Noninferior to 12 Months with Second-Generation DES

Post-discharge Bleeding Common, Predictive of Mortality After PCI

New Study Examines the Optimal Duration Time of Dual Anti-Platelet Therapy in Patients with Second-Generation Drug-Eluting Stents

New Study Evaluates “Triple Therapy” Regimens After Drug-Eluting Stenting in Patients Requiring Oral Anticoagulation

Less Mortality with Paclitaxel-Coated Balloon vs. Stent in DES Restenosis

Keynote Address Focuses on Newer DES, Problematic Subgroups

COMBO Stent Achieves Neointimal Regression at 24 Months

Abbott Initiates ABSORB IV Trial to Evaluate Quality of Life and Cost Savings of Dissolving Heart Device

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content